Literature DB >> 15315841

Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting.

Qing-Min Wang1, Shu-Han Sun, Zhen-Lin Hu, Ming Yin, Cun-Jie Xiao, Jian-Cheng Zhang.   

Abstract

The study evaluated the immune response elicited by a DNA vaccine encoding ESAT6 protein of Mycobacterium tuberculosis by DNA prime-protein boost protocol. BALB/c mice were respectively vaccinated with plasmid DNA encoding ESAT6 protein, with ESAT6 protein in IFA adjuvant, or a combined DNA prime-protein boost regimen. While DNA immunization induced Th1-polarized immune response, protein-in-adjuvant vaccination elicited a Th2-dominant response. When animals were primed with DNA and boost with protein, both antibodies and Th-cell proliferative response were significantly enhanced. Moreover, production of Th1-type cytokine (IFN-gamma) was increased significantly by DNA priming-protein boosting. This protocol also resulted in an increased relative ratio of IgG2a to IgG1 and the cytotoxicity of T cells. Thus, this study demonstrated that the formation of ESAT6 DNA prime-protein boost inoculation could improved antigen-specific cellular immune responses, which are important for protection against TB infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315841     DOI: 10.1016/j.vaccine.2004.03.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 2.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

3.  Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model.

Authors:  Sivasakthivel Thirugnanam; Pandurangan Pandiaraja; Kalyanasundaram Ramaswamy; Vadivel Murugan; Munirathinam Gnanasekar; Krithika Nandakumar; Maryada Venkata Rami Reddy; Perumal Kaliraj
Journal:  Exp Parasitol       Date:  2007-03-06       Impact factor: 2.011

4.  Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.

Authors:  Saumyabrata Mazumder; Mithun Maji; Amrita Das; Nahid Ali
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

5.  Induction of Specific CD8 T Cells against Intracellular Bacteria by CD8 T-Cell-Oriented Immunization Approaches.

Authors:  Toshi Nagata; Yukio Koide
Journal:  J Biomed Biotechnol       Date:  2010-05-24

6.  DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Authors:  H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

Review 7.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

8.  Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Authors:  Laura E Johnson; Dirk Brockstedt; Meredith Leong; Peter Lauer; Erin Theisen; John-Demian Sauer; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

Review 9.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

10.  Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice.

Authors:  Yan Liang; Xuejuang Bai; Junxian Zhang; Jingying Song; Yourong Yang; Qi Yu; Ning Li; Xueqiong Wu
Journal:  Mol Med Rep       Date:  2016-06-03       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.